KFAS
ACAD icon

Keating Financial Advisory Services’s Acadia Pharmaceuticals ACAD Stock Holding History

Keating Financial Advisory Services’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$759 Sell
30
-63
-68% -$1.39K ﹤0.01% 2256
2026
Q1 		$2.07K Buy
93
+40
+75% +$956 ﹤0.01% 1832
2025
Q4 		$1.42K Buy
+53
New +$1.27K ﹤0.01% 1695

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Keating Financial Advisory Services's ACAD Position: Q2 2026 in Review

Keating Financial Advisory Services reduced its Acadia Pharmaceuticals (ACAD) stake by 68% in Q2 2026, selling an estimated $1.39K and leaving 30 shares worth $759. The position accounts for ﹤0.01% of the portfolio, ranked #2256.

Keating Financial Advisory Services first reported a position in ACAD in Q4 2025 and has held it in 3 quarters since. The position peaked at $2.07K in Q1 2026. 354 funds tracked by Wall St. Rank hold ACAD as of Q2 2026.

  • Keating Financial Advisory Services held 30 shares of Acadia Pharmaceuticals worth $759 as of Q2 2026.
  • Keating Financial Advisory Services sold 63 Acadia Pharmaceuticals shares in Q2 2026, an estimated $1.39K.
  • Acadia Pharmaceuticals made up ﹤0.01% of Keating Financial Advisory Services's portfolio in Q2 2026, its #2256 holding.
  • Keating Financial Advisory Services first reported a position in Acadia Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
  • Keating Financial Advisory Services's Acadia Pharmaceuticals position peaked at $2.07K in Q1 2026.
  • 354 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q2 2026.

Based on Keating Financial Advisory Services's 13F filing for Q2 2026, filed 11 Aug 2026.